Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Erratum: Targeting MET in cancer: rationale and progress

The Original Article was published on 24 January 2012

Nature Reviews Cancer 12, 89–103 (2012)

In the legend to Figure 6c, the distribution according to therapeutic strategy (monotherapy versus combined therapy) involving HGF/SF–MET monotherapies should have read 44%. This has been corrected on both html and pdf versions.

Authors

Additional information

The online version of the original article can be found at 10.1038/nrc3205

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gherardi, E., Birchmeier, W., Birchmeier, C. et al. Erratum: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12, 637 (2012). https://doi.org/10.1038/nrc3367

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing